FDA panel backs Auxilium's Xiaflex therapy

Auxilium Pharmaceuticals won the unanimous backing of an FDA advisory panel for its experimental therapy to treat Dupuytren's contracture. The panel said that Xiaflex is a safe and effective alternative to surgery as a treatment for a condition that afflicts the connective tissue in the hand. Trading in Auxilium's shares had been halted ahead of the vote.

Some seven million to 14 million people suffer from Dupuytren's disease, a buildup of collagen that leaves fingers bent, with patients unable to extend them normally. Surgery has been the only therapy available. The FDA doesn't have to follow the advice of its expert panels, but it usually does. And a unanimous vote would be hard to overlook.

"We are very pleased with the advisory committee's recommendation," said Armando Anido, Auxilium's chief executive. "Xiaflex has the potential to provide an important new nonsurgical treatment option for patients with Dupuytren's contracture, a debilitating hand condition severely affecting patients' quality of life."

- check out the report from the Wall Street Journal
- read the post from StreetInsider 

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.